A venture capital firm that founded in 2000 and is based in the US Midwest has assets under management of over $250 million, and closed a new fund in 2015. The fund typically makes equity investments in U.S.-based companies, with portfolio companies located on both coasts and throughout the central part of the country. The firm will consider investing at all stages, with a focus on seed and early-stage investments, including founding companies. Investment size is up to $12 million throughout a portfolio company’s path to liquidity.
The fund is currently looking for new investment opportunities in the life science space, with a specific focus on biopharmaceuticals and therapeutic medical devices. The firm has previously invested in drugs to treat cancer and cardiac disorders, and in minimally invasive medical devices. The fund does not invest in diagnostics, though may be interested in technology with real-time feedback for procedures.
The fund focuses on identifying and shaping early-stage life science companies in the series A/B rounds to create significant shareholder value. Because of its extensive operating expertise, the fund is able to help entrepreneurs achieve near-term objectives that position their companies for exit.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment